Investor Presentation Q1-Q3 2020
41
Investor presentation
First nine months of 2020
Novo Nordisk global insulin market leadership expanded to
46.9% and the global insulin volume market grew by 2.8%
North America Operations
Market growth: 0.2%
MS: 39.6%
MS gain/loss: -0.3%-p
Sales growth: -22%
Global
Market growth: 2.8%
MS: 46.9%
MS gain/loss¹: 0.4%-p
Sales growth: -3%
International Operations
Market growth: 3.8%
MS: 49.7%
MS gain/loss: 0.6%-p
Sales growth: 10%
USA
Market growth: 0.2%
MS: 39.5%
MS gain/loss': -0.6%-p
Sales growth: -23%
Source: IQVIA MAT, Aug 2020 volume figures
Note: Sales growth for first nine months of 2020 at constant exchange
rates; Market shares are for Novo Nordisk and market growth for the total
insulin market
1MS gain/loss compared with Aug 2019 reported MS
EMEA: Europe, Middle East, Africa; MS: Market share; RoW: Asia Pacific; Latin
America;
EMEA
Market growth: 2.7%
MS: 47.2%
MS gain/loss: 0.4%-p
Sales growth: 6%
ROW
Market growth: 6.2%
MS: 57.0%
MS gain/loss: 1.1%-p
Sales growth: 12%
Region China
Market growth: 5.1%
MS: 49.5%
MS gain/loss': -0.6%-p
Sales growth: 14%
Novo NordiskⓇView entire presentation